How to tackle the future financial challenges in Personalised Medicine in Europe?
How to tackle the future financial challengesin Personalised Medicine in Europe?Dr Wouter Spek, Managing director EuroBioForum24 April 2013 *EPEMED webinar
OVERVIEW webinar• Introduction– W. Spek & EuroBioForum– Situation in Europe now1. What is the role of funders?2. What kind of financial incentives we need?3. How can we achieve convergence• Conclusions– Live discussion
WOUTER SPEK• PhD in biology– Leiden University (NL) & University California, San Diego (USA)• Some 20 years of experience (RDTI strategy & finance)– Biotech > Genomics > Life Sciences > Pmed• International– FPs, COST, EUREKA, HTC (USA), BILAs (NL-FR)– Advisor Dutch Ministry of Economic Affairs (FP5 & FP6)• One of the founding fathers– Netherlands Genomics Initiative– ERA-NET on Plant Genomics• Consultant since 2008
EuroBioForum• Forum for research funders and performersin Personalised Medicine in Europe• Scout + Connect + Activate– Annual Conferences – 2012, 2013, 2014– Personalised Medicine Observatory– Community development– Satellite meetings for special interest groupswww.eurobioforum.eu
EUROPE now• Fragmented– Let a thousand flowers bloom!• How to deal with the institutional barriers?• Limited convergence & little incentives• High level of public investments• Weak communication & information systems• Enough future-orientated?
Europe 2020: We need an integral chainapproach, bound by coordinated actions and strategicagenda,amongst all stakeholders at stake!
FUNDERS• Public funders– National (many per country)– European Commission• Private funders– Banks, VCs– Industry related– Charities & foundations• New breed funders– Crowdfunding– Prize competitions
How to align 1,000 projects to improver.o.i. and deliver better healthcare for all?